A Study of Accelerated Guideline-Directed Medical Therapy for Heart Failure

Completed

Conditions studied: Heart Failure

In brief

The aim of the study was to evaluate the efficacy and safety of a Guideline-Directed Medical Therapy (GDMT) clinic within a general cardiology practice relative to usual care. This study analyzed data from patients with heart failure (HF) who were referred to the GDMT clinic at Massachusetts General Hospital (MGH). For the comparator arm, patients in the GDMT clinic were matched to data of patients contained within in the MGH Research Patient Data Repository (RPDR).

Key facts

Study ID

NCT07217106

Run by

Novartis Pharmaceuticals

People needed

342

Starts

2024-03-03

Expected to finish

2024-07-01

Last updated by the study team

2025-10-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of HF, including new onset disease
• Established cardiovascular follow up at the hospital
• Received sub-optimal medical care defined as <50% target doses of GDMT agents
• Left ventricular ejection fraction (LVEF) <50%

You may not qualify if…

• Planned referral to the Advanced HF program
• Decompensated HF
• End-stage kidney disease
• o glomerular filtration rate (GFR) <15 mL/min/1.73m\^2 or on renal replacement therapy
• Untreated severe valvular heart disease
• Advanced HF
• Inotropic support
• Transplant or mechanical circulatory support (MCS) planned
• Enrolled in hospice or palliative care
• Life expectancy <12 months due to non-cardiovascular (CV) disease
• Pericardial constriction
• Hypertrophic cardiomyopathy
• Unwillingness or inability to take GDMT
• Pregnancy or breast feeding

Where it is running

• Novartis — East Hanover, New Jersey, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.